A Phase Ia/Ib, Open Label, Multicentre, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumours
This study is open to adults with different types of advanced cancer (solid tumours). The purpose of this study is to find out the highest dose of BI 907828 the participants can tolerate. In the second part, the study also tests whether BI 907828 makes tumours shrink. In this study, BI 907828 is given to humans for the first time. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. BI 907828 is taken as a tablet. Participants either take a dose of BI 907828 on one day every 3 weeks or on one day in 2 consecutive weeks every 4 weeks. The participants are in the study for as long as they benefit from and can tolerate treatment. The doctors regularly check the participants' general health during the study.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society